

PRESS RELEASE

Sonio raises €5M to improve women's and children's health by securing pregnancy care with AI



Paris, June 29th 2022 - [Sonio](#), a French start-up created in 2020 and developing an artificial intelligence software that empowers fetal medicine professionals to secure pregnancy care, announces a €5m fundraise led by [Elaia](#), alongside [OneRagtime](#) and [Bpifrance](#). This fundraise will allow Sonio to accelerate on three fronts: adding embedded image recognition into the Sonio platform, preparing the market entry in the US and FDA clearance, and ramping up sales in Europe.

In order to improve access and quality of care for pregnant women and children, Sonio leverages 5 years of R&D and clinical development at Ecole Polytechnique, the Prairie Institute and Necker Hospital in Paris. The company has brought together unique expertise from the fields of fetal medicine, artificial intelligence, software development and imaging to address the 50% of congenital malformations that are not detected before birth with a comprehensive solution to assist all fetal ultrasound practitioners, from beginners to the most seasoned experts. It is already being used by 150 healthcare professionals in Europe.

"We're delighted to welcome seasoned digital health investors to Sonio's capital." said Cécile Brosset, Chief Executive Officer and co-Founder of Sonio. "Sonio addresses very important issues for both pregnant women and fetal medicine practitioners with a unique combination of artificial intelligence and clinical expertise. This new round of financing will allow us to recruit the talents we need both in software development and sales, and bring to the market our full suite of products."

In 2 years, the multidisciplinary, mission-driven team managed to bring one first product to the market, getting CE mark and first clients in record time. Several partnerships have already been signed, with Samsung France, one of the main ultrasound manufacturers, but also with private clinics like PointGyn (OneClinic) in France and GynEcho in Canada. Precious support from successful medtech entrepreneurs (Yann Fleureau (Cardiologs), John Gridley (BioSignal)) and femtech business angels (Alain Decombe, Dominique Gaillard, Pauline Duval) will help Sonio prepare the ground for profitable growth both in Europe and the United States.

"We have found all key ingredients for success in Sonio: a seasoned and market savvy team of founders, a solid and patented deep technology platform, and a market ready for take off, as evidenced by existing customers and commercial partners" said Benoît Georis, Investment Director at Elaia.

“After supporting Sonio with convertible bonds under the French Tech Seed Fund, Bpifrance is proud to support its commercial acceleration and its technological innovations. We were seduced by the unique user experience offered by the platform and its ability to secure practice by creating value for all medical staff and patients.” Eva Clerc, Investment Director at Bpifrance.

“At OneRagtime, we have been seduced by Sonio’s vision to leverage artificial intelligence to improve pregnant women’s health and empower practitioners in prenatal screening and diagnosis. We are proud to support the company in its roadmap and commercial expansion across Europe and the US. We are fully convinced by the team’s experience and ability to execute this innovative business and become the reference in prenatal care.” says Stéphanie Hospital, Founder and CEO at OneRagtime.

About Sonio

Founded in 2020, Sonio is the only SaaS platform that empowers healthcare professionals to secure prenatal care by combining technological innovation, medical expertise, and collective intelligence. It provides a unique Artificial Intelligence software that associates the knowledge of prenatal medicine practitioners with all types of medical, imaging, genetic and environmental data to optimize prenatal screening and diagnosis.

Created by a team of entrepreneurs (Cécile Brosset, Dagmar Nuber) and scientific (Rémi Besson, Stéphanie Allasonnière, Erwan Le Pennec), medical (Yves Ville, Julien Stirnemann, Emmanuel Spaggiari) and tech experts (David Amouyal, Deepak Prakash), Sonio is already being used by 150 healthcare professionals in Europe.

Sonio is committed to become an “Entreprise à Mission” – a company whose objectives in the social, societal, and environmental fields are aligned with this purpose and set out in its by-laws, as defined by the 2019 PACTE law.

www.sonio.ai